R

Avita Medical
D

RCEL

9.76000
USD
-0.21
(-2.11%)
مغلق
حجم التداول
5,698
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
257,249,610
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADAP
    -0.01800
    (-3.11%)
    0.56000 USD
    A
    ARDX
    -0.65000
    (-11.39%)
    5.05500 USD
    B
    BCRX
    -0.17000
    (-1.81%)
    9.20000 USD
    N
    NAOV
    -0.00740
    (-1.93%)
    0.37560 USD
    P
    PLRX
    0.08000
    (2.66%)
    3.08500 USD
    P
    PSTV
    -0.09000
    (-6.98%)
    1.20000 USD
    V
    VCEL
    -2.230
    (-4.11%)
    52.060 USD
    المزيد
الأخبار
المقالات

العنوان: Avita Medical

القطاع: Healthcare
الصناعة: Medical Devices
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.